Abstract
8-(3-Isothiocyanatostyryl)caffeine (ISC) was synthesized and shown to inhibit selectively the binding of [3H]CGS 21680 (an A2a-selective agonist) at adenosine receptors in striatal membranes. The Ki value at A2a-receptors was found to be 110 nM (rat), with selectivity ratios for A2a versus A1-receptors in rat, guinea pig, bovine, and rabbit striatum of >100-fold. Preincubation of membranes with ISC caused a dose-dependent, irreversible antagonism of the binding of [3H]CGS 21680, with an IC50 value of 3 μM. The irreversibility is likely due to the presence of the chemically reactive isothiocyanate group, since the binding of the corresponding analogue in which the isothiocyanate was replaced with a chloro group was completely reversible. The potency of ISC to irreversibly inhibit the binding of [3H]CGS 21680 in several species varied in the order rat ≈ guinea pig > bovine ≈ rabbit. In all four species, binding of the A1-selective agonist [3H]R-N6-phenylisopropyladenosine was not diminished by pre-treatment with 2 μM ISC. The kinetics of irreversible inhibition of rat A2a-receptors by 2 μM ISC gave a t1/2 of approximately 3 min. Following partial inactivation, the remaining rat A2a-binding sites retained the same Kd value as in control membranes for saturation by [3H]CGS 21680. Thus, ISC appears to be a selective affinity label for A2a- versus A1-receptors in the brain.
Keywords: xanthines, affinity label, adenosine receptors, radioligand binding
INTRODUCTION
Adenosine acts as a neuromodulator in the central and peripheral nervous systems [reviewed in Ferré et al., 1992, Olsson and Pearson, 1990]. As a local hormone in a variety of organs, it decreases the oxygen consumption (as in its negative chronotropic action in the heart, through activation of A1 receptors) and increases oxygen supply (for example, through activation of vascular A2a receptors) in response to stress [Bruns, 1991]. In the CNS, A2a receptors are present in high density in the striatum, where they have been studied using radioligand binding techniques [Bruns et al., 1986; Barrington et al., 1989]. Other tissues in which radioligand binding to A2a receptors has been characterized include platelets [Lohse et al., 1988], pheochromocytoma (PC12) cells [Hide et al., 1992], and smooth muscle (DDT1-MF2) cells [Ramkumar et al., 1991]. A2a receptors are linked via Gs guanine nucleotide binding proteins to the stimulation of adenylate cyclase. A2b receptors [Bruns et al., 1986], through which adenosine agonists also stimulate adenylate cyclase, but at higher concentrations, are found in the brain, fibroblasts, and intestines [Stehle et al., 1992].
We have developed novel pharmacological probes, including radioligands and photoaffinity labels [Barrington et al., 1990], fluorescent labels [Mc-Cabe et al., 1993], and chemically reactive affinity labels [Jacobson et al., 1989, 1992], as tools for the characterization of adenosine receptors. Binding site-directed affinity labels for A1-receptors (agonists and antagonists) and A2a-receptors (agonists) have been synthesized based on a functionalized congener approach. Recently, 8-styrylxanthine derivatives that act as A2a-selective adenosine antagonists have been reported [Shimada et al., 1992]. We now introduce an 8-styrylxanthine isothiocyanate derivative that acts as a selective irreversible inhibitor of binding to A2a-receptors. The design of this agent was based on a detailed structure activity study [Jacobson et al., 1993] of this class of xanthines.
EXPERIMENTAL PROCEDURES
Materials
2-Chloroadenosine was obtained from Research Biochemicals, Inc. (Natick, MA). 1,3,7-Trimethyl-8-(3-aminostyryl)xanthine, 1, and the 3-chloro analogue, 3, were prepared as described [Jacobson et al., 1993]. [3H]N6-phenylisopropyladenosine, and [3H]CGS 21680 were obtained from Dupont NEN (Boston, MA).
Synthesis of 8-(3-Isothiocyanatostyryl)caffeine, 2
1,3,7-Trimethyl-8-(3-aminostyryl)xanthine (50 mg, 0.16 mmol) was dissolved in 2 ml chloroform, and saturated sodium bicarbonate solution (1 ml) was added. After cooling the mixture in an ice bath, thio-phosgene (0.1 ml, 1.3 mmol) was added at once with vigorous stirring. After 5 min, the reaction was complete and additional solvent was added to break the emulsion. The phases were separated, and the organic phase was washed several times with water and dried (MgSO4). The solvent was evaporated, and the solid yellow residue was recrystallized from chloroform/acetonitrile to provide 32 mg (57% yield) of the homogeneous product, 8-(3-isothiocyanatostyryl)caffeine or 1,3,7-trimethyl-8-(3-isothiocyanatostyryl)xanthine hemi-hydrate (TLC system chloroform: methanol: acetic acid, 95:4:1, Rf = 0.41) Mp 268–271°C. 1H NMR CDCl3 δ 3.43 (s, 3H N-CH3); 3.63 (s, 3H N-CH3); 4.07 (s, 3H N7-CH3); 6.93 (d, 1H J = 16Hz, olefin); 7.21 (d, 1H J = 8Hz); 7.39 (t, 1H J = 8Hz, C5 arom); 7.44 (s, 1H, C2 arom); 7.47 (d, 1H J = 8Hz); 7.75 (d, 1H J = 16Hz, olefin). MS (El) M + 353. IR (NaBr) 2124 cm−1. Elemental analysis (C17H15N5O2S.0.5H2O): calculated, 56.34% C, 4.45% H, 19.33% N; found 56.43% C, 4.16% H, 19.07% N.
Biochemical Assays
Preparation of striatal membranes
Striatal tissue was isolated by dissection of rabbit, bovine, and rat brain, obtained frozen from Pel-Freeze Biologicals Co. (Rogers, AS), and guinea pig brain, obtained frozen from Keystone Biologicals (Cleveland, OK). Membranes were homogenized in 20 volumes of ice cold 50 mM Tris HCl (pH 7.4) using a Polytron (Kinematica Gmbh, Luzern, Switzerland) at a setting of 6 for 10 sec. For each species except rat, the homogenization was carried out in the presence of protease inhibitors (5 mM EDTA, 0.1 mM phenylmethanesulfonyl fluoride, 0.01 mg/ml soybean trypsin inhibitor, 5 μg/ml leupeptin, 1 μg/ml pepstatin A). The membrane suspension was then centrifuged at 37,000g for 10 min at 4°C. The pellet was resuspended (20 mg tissue/ml) in the above buffer solution, preincubated at 30°C for 30 min with 3 IU/ml of adenosine deaminase, and the membranes were again homogenized and centrifuged. Finally the pellet was suspended in buffer (100 mg wet weight per ml) and stored frozen for no longer than 2 weeks at − 70°C. Protein was determined using the BCA protein assay reagents (Pierce Chemical Co., Rock-ford, IL).
Treatment of striatal membranes with inhibitor
Membranes were incubated with ISC in pH 7.4 Tris buffer containing adenosine deaminase, for 1 h at 25°C, subjected to three washing cycles, consisting of centrifugation at 37,000g and resuspended of the pellet in Tris buffer, prior to radioligand binding. For kinetic experiments with the affinity label, aliquots were removed periodically and quenched with a large volume of buffer solution (30 ×) prior to radioligand binding. For protection experiments, membranes were preincubated with theophylline at 25°C for 20 min, and then ISC was added immediately for an additional incubation at 25°C for 30 min. At the end of this sequence, the membranes were washed by repeated centrifugation and resuspension and subjected to 2-(carboxyethylphenylethylamino)adenosine-5′-carboxamide ([3H]CGS 21680) binding.
Washing cycles for inhibition experiments required resuspending the membrane pellet by gentle vortex mixing. At the final step, prior to radioligand binding, the membranes were homogenized manually using a glass tissue grinder.
Radioligand binding
[3H]CGS 21680 binding to striatal A2a-receptors from rat, guinea pig, rabbit and bovine brains was carried out as described for rat brain [Jarvis et al., 1989] using 10 μM 2-chloroadenosine to determine non-specific binding. Adenosine deaminase was present (3 IU/ml) during the incubation with radioligand.
The binding of [3H]R-PIA to striatal A1-receptors in four species was measured by a modification of the method described for rat cortex [Jacobson et al., 1993]. In competition studies, to avoid precipitation of the xanthine in the 100 μM concentration range, the tubes in that range containing all components were warmed to ~50°C, prior to the incubation carried out for 90 min at 37°C.
For saturation and competition studies, Bmax, Kd, and IC50 values were determined using the Ligand [Munson and Rodbard, 1980] and Inplot (Graphpad, San Diego, CA) computer programs. IC50 values were converted to apparent Ki values using KD values in rat striatum of 1.0 and 15 nM for [3H]PIA and [3H]CGS 21680 binding, respectively, and the Cheng-Prusoff equation [Cheng and Prusoff, 1973].
RESULTS
An isothiocyanate derivative (1,3,7-trimethyl-8-(3-isothiocyanato-styryl)xanthine, ISC, 2) in the A2-selective, 8-styrylxanthine series of adenosine antagonists [Shimada et al., 1992; Jacobson et al., 1993] was prepared as a potential receptor affinity label. It was synthesized by reaction of the corresponding 3-amino derivative [Jacobson et al., 1993], 1, with thiophosgene (Fig. 1). The previously noted difficulty of treating 1,3-disubstituted xanthines with thiophosgene [Jacobson et al., 1989] was not encountered with this 1,3,7-trisubstituted xanthine. The decomposition noted previously was likely due to involvement of the imidazole group, which is N-alkylated in this case. The meta-position was selected as the site of styryl substitution with an isothiocyanate group, based on structure activity relationships [Jacobson et al., 1993], suggesting that the mono-, meta-substitution favored selectivity and potency at rat striatal A2a-receptors.
Figure 1.
Structures and synthesis of xanthine derivatives used in this study. The 3-amino derivative, 1, was converted to the isothiocyanate, ISC, 2, using thiophosgene. The 3-chloro derivative, 3, is also selective for A2a-receptors, but is not chemically reactive.
Competition by ISC of binding of [3H]CGS 21680 (an A2a-selective agonist) and [3H]R-PIA (an A1-selective agonist) in striatal membranes from four species was measured (Table 1) under “reversible” conditions. Major species differences have been noted previously for xanthines binding at A2a-adenosine receptors [Stone et al., 1988]. In rat striatum, the IC50 at A2a-receptors was found to be 146 nM (corresponding to an apparent Ki value of 111 nM, assuming reversibility). At A1-receptors the IC50 was found to be 43 μM (corresponding to a Ki value of 20 μM). Thus, the selectivity ratio of ISC for A2a- versus A1-receptors in the rat based on IC50 values was 290-fold (180-fold, based on Ki values). The selectivity ratio in guinea pig striatum was nearly identical. In other species A2a-selectivity was maintained (bovine, 120-fold, and rabbit, 180-fold), although the affinity was diminished. At rabbit A2a receptors, the apparent Ki value of ISC was 290 nM based on the reported Kd value of 28.6 nM for binding of [3H]CGS 21680 [Jacobson et al., 1992]. The Hill coefficients for displacement of binding of [3H]CGS 21680 in the four species were approximately equal to 1. The A2-selectivity of ISC was consistent with the previously determined A2-selectivity [Jacobson et al., 1993] of the amino precursor, 1, and the 3-chloro derivative, 3 (30-fold and 520-fold selectivity, respectively, based on Ki values).
TABLE 1.
Potencies of ISC in Inhibiting Radioligand Binding at Central A1 and A2a Receptors in Four Mammalian Species.*
| Species | IC50(A1) | IC50(A2) | A1/A2 ratio |
|---|---|---|---|
| Rat | 42,600 ± 3600a | 146 ± 3b | 291 |
| Guinea pig | 51,400 ± 17,700 | 160 ± 2 | 320 |
| Bovine | 63,400 ± 5,900 | 516 ± 64 | 122 |
| Rabbit | 89,500 ± 2,000 | 413 ± 135c | 217 |
Expressed in nM (mean ± s.d. for 3 or more determinations) vs. [3H]PIA (1 nM) at striatal A1-receptors and vs. [3H]CGS 21680 (5 nM) at striatal A2a-receptors. Non-specific binding was determined in the presence of 10 μM 2-chloroadenosine.
Corresponds to a Ki value of 20,300 ± 1700 nM.
Corresponds to a Ki value of 111 ± 0.5 nM and a selectivity ratio of 182.
Corresponds to a Ki value of 347 ± 112 nM.
ISC was examined for the ability to irreversibly inhibit A2a-receptors. Preincubation of rat striatal membranes with ISC caused a dose-dependent, irreversible antagonism of the binding of 5 nM [3H]CGS 21680 (an A2a-selective agonist), with an IC50 value of 2.7 μM (Fig. 2A). This IC50 value was 18-times greater than the IC50 value in competitive displacement of [3H]CGS 21680 in the same tissue (Table 1). Preincubation with 20 μM ISC resulted in the loss of approximately 80% of the specific binding of [3H]CGS 21680. The irreversible nature of inhibition by the isothiocyanate derivative was demonstrated by the failure of repeated washing to regenerate the A2a-receptor binding site. Nearly all of the binding of [3H]N6-phenylisopropyladenosine (PIA) to striatal A1 receptors was recovered following washout by repeated cycles (4x) of centrifugation and resuspension of the membranes in fresh buffer. Thus, at A1-adenosine receptors in rat striatal membranes, ISC at a high concentration of 20 μM was barely effective as an irreversible inhibitor. At this concentration only 12 ± 3% of [3H]PIA binding was lost compared to 81 ± 2% of [3H]CGS 21680 binding.
Figure 2.
Dose-dependent irreversible inhibition by ISC of radioligand binding at A1- (open symbols) and A2a- (solid symbols) adenosine receptors in A) rat, B) guinea pig, C) bovine, and D) rabbit striatal membranes (n = 4 or more). The preincubation with ISC or control was carried out for 1 h at 25°C, and the subsequent binding assay involved a 90 min incubation followed by rapid filtration. The radioligand binding step consisted of incubation in triplicate with 5 nM [3H]CGS 21680 for A2a-receptors or 1 nM [3H]PIA for A1-receptors. Each data point represents the mean ± s.d. specific binding for 3–4 separate experiments. In A, error bars at 10 and 20 μM ISC are obscured by the data point.
Exposure of the ISC-treated striatal membranes to the weak adenosine antagonist 3-isobutyl-1-meth-ylxanthine (IBMX, 100 (μM) overnight also did not regenerate any A2a-receptor binding (data not shown). Treatment with IBMX was used to removed non-chemically bound ligand from the membranes in a previous study of chemically reactive xanthines as irreversible inhibitors of A1 receptors [Jacobson et al., 1989]. Such treatment was found to be unnecessary in this study, since no difference in binding was observed. Increasing the temperature of preincubation with ISC to 37°C also did not affect significantly the fraction of binding irreversibly inhibited (data not shown).
The irreversibility was examined in three other species (Figs. 2B–D). In the guinea pig striatum, the inhibition occurred at concentrations similar to those used with rat striatum (EC50 value 2.8 (μM). In rabbit and bovine striatum, ISC caused an irreversible inhibition of A2a receptors, but at considerably higher concentrations than in rat striatum. The EC50 values for ISC irreversibly inhibiting bovine and rabbit A2a receptors were 8 and 10 μM, respectively.
The irreversibility is likely due to the presence of the chemically reactive isothiocyanate group, since the binding of the corresponding analogue in which the isothiocyanate was replaced by a chloro group, 3, was completely reversible (data not shown).
To study the time course for inactivation of rat A2a receptors a concentration of 2 (μM ISC was used. This concentration corresponds to 14-fold greater than the IC50 value for ISC in this species in the “competitive” binding assay vs. [3H]CGS 21680 (Table 1). The inactivation was rapid (Fig. 3), although the degree of irreversible inhibition was not complete even after 2 h. Approximately 3 min was required for inhibition of 50% of its final value at 2 h (at 2 h approximately 55% of the specific [3H]CGS 21680 binding relative to control membranes was lost). The fraction of receptors inactivated by this isothiocyanate derivative increased as the concentration of ISC was raised (Fig. 2).
Figure 3.
Time course for inhibition of specific binding to rabbit striatal A2a-adenosine receptors at 25°C by 2 μM ISC. The membranes were washed by centrifugation (3x) prior to radioligand binding. [3H]CGS 21680 was used at a concentration of 5 nM. This curve is representative of data from three separate experiments.
Saturation of binding of [3H]CGS 21680 to rat striatal receptors following treatment with ISC (Fig. 4) and washing was measured. Following a preincubation with 5 μM ISC resulting in partial inhibition, at the remaining A2a sites the Bmax value relative to control membranes was reduced without a significant effect on the Kd value. The Kd value for [3H]CGS 21680 binding was 15.7 nM, and the Bmax value was 450 fmol/mg protein after pretreatment with ISC, versus 14.3 nM and 900 fmol/mg protein for control.
Figure 4.
Saturation curve (A) and Scatchard transformation (B) for the specific binding of [3H]CGS 21680 to A2a-adenosine receptors in rat striatal membranes, in control membranes (open circles) and following preincubation at 25°C for 1 h with 2 μM ISC (closed circles). The volume of incubation for radioligand binding (approximately 150 μg protein/tube) was 1 ml. Membranes were incubated with radioligand at 25°C for 90 min. Specific binding in control (○) and treated (●) membranes is shown. Non-specific binding in control and treated membranes was nearly identical and amounted to 8–10% of total binding at 5 nM [3H]CGS 21680.
Inhibition of binding of [3H]CGS 21680 at A2a-receptors by ISC could be prevented by the adenosine receptor antagonist theophylline. The receptor was protected in the presence of 1 mM theophylline, with degrees of protection of 45% and 37% at 0.5 μM and 2 μM ISC, respectively (Fig. 5).
Figure 5.
Protection by theophylline of rat striatal A2a receptors from inhibition by ISC. Percent irreversible inhibition relative to the level of specific binding of 5 nM [3H]CGS 21680 in control membranes is shown (n = 3). Hatched bars are for ISC alone, at the indicated concentration. Solid bars are for the combination of ISC and theophylline (1 mM).
DISCUSSION
The isothiocyanate (—N=C=S) group is frequently used as a chemically reactive group for incorporation into receptor affinity labels, including irreversible inhibitors of adenosine receptors [Jacobson et al., 1989]. An aryl isothiocyanate has a favorable balance of stability in aqueous medium and reactivity towards nucleophiles present on proteins, such as amino and thiol groups.
ISC appears to be a selective affinity label of moderate affinity for A2a- versus A1-receptors in four species. The affinity of ISC at low affinity A2b-receptors [Bruns et al., 1986; Hide et al., 1992] has yet to be determined.
The chemical mechanism for the irreversibility is presumably acylation by the reactive isothiocyanate group of a nucleophilic group located on or in the vicinity of the antagonist binding site of the receptor protein. Following partial inactivation, the remaining rat A2a-binding sites retained the same Kd value for saturation by [3H]CGS 21680. Thus, the inhibition is all-or-none, consistent with covalent anchoring of the ligand in its usual binding site.
ISC is of potential utility in characterization of the binding of xanthines to adenosine receptors at the molecular level. The amino acid sequence of A2a receptors in several species is known [Maenhaut et al., 1990; reviewed in van Galen et al., 1992; Linden et al., 1993]. The site of presumed reaction with the receptor protein may be characterized in future studies through radiolabeling the isothiocyanate derivative for purposes of peptide mapping and by site-directed mutagenesis. Unlike previous irreversible inhibitors of adenosine receptors [Jacobson et al., 1989, 1992], in which an isothiocyanate group was positioned on a functionalized chain at a large distance from the pharmacophore, this NCS group is located close to the purine moiety. Thus, ISC may be especially helpful in identifying amino acid residues that are in proximity to the xanthine binding site.
In order to confirm that ISC is an irreversible antagonist of adenosine receptor activation, it will be necessary to study its functional effects on adenylate cyclase activity. Such selective inhibitors are also potentially of interest in physiological studies, in defining the roles of adenosine receptor subtypes. By analogy, an A2a agonist-derived affinity label, 2-[2-[4-[2-[ [ [ (4 - isothiocyanatophenyl)aminothiocarbonylamino-ethyl]-amino]carbonyl]ethyl]phenyl]ethylamino]-5′-N-ethylcarboxamidoadenosine (p-DITC-APEC) has been studied in the isolated, perfused guinea pig heart [Niiya et al., 1993] and found to cause a prolonged coronary vasodilatation. An A1 antagonist-derived affinity label, (8-[4-[[[[[2-(3-isothiocyanatophenyl) aminothiocarbonylaminoethyl]-amino] carbonyl] methyl]oxy]phenyl]-1,3-dipropylxanthine) (m-DITC-XAC) was used to demonstrate the presence of spare adenosine receptors in the guinea pig atrioventricular node [Dennis et al., 1992]. It is possible that ISC will also be useful in vivo. Other aryl isothiocyanate-bearing affinity labels have been administered in vivo [de Costa et al., 1989] and found to be sufficiently stable to label their receptor sites in the brain and elsewhere.
Acknowledgments
C.G. is grateful for financial support from the Cystic Fibrosis Foundation.
References
- Barrington WW, Jacobson KA, Hutchison A], Williams M, Stiles GL. Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc Natl Acad Sci USA. 1989;86:6572–6576. doi: 10.1073/pnas.86.17.6572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bruns RF. Role of adenosine in energy supply/demand balance. Nucleosides and Nucleotides. 1991;10:931–943. [Google Scholar]
- Bruns RF, Lu GH, Pugsley TA. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol. 1986;29:331–346. [PubMed] [Google Scholar]
- Cheng YC, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzyme reaction. Biochem Pharmacol. 1973;22:3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
- de Costa BR, Band L, Rothman RB, Jacobson AE, Bykov V, Pert A, Rice KC. Synthesis of an affinity ligand (“UPHIT”) for in vivo acylation of the kappa opioid receptor. FEBS Lett. 1989;249:178–182. doi: 10.1016/0014-5793(89)80619-2. [DOI] [PubMed] [Google Scholar]
- Dennis D, Jacobson K, Belardinelli L. Evidence of spare A1-adenosine receptors in guinea pig atrioventricular node. Am J Physiol. 1992;262:H661–H671. doi: 10.1152/ajpheart.1992.262.3.H661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ferré S, Fuxe K, von Euler G, Johansson B, Fredholm BB. Adenosine-dopamine interactions in the brain. Neuroscience. 1992;51:501–512. doi: 10.1016/0306-4522(92)90291-9. [DOI] [PubMed] [Google Scholar]
- Hide I, Padgett WL, Jacobson KA, Daly JW. A2a-Adenosine receptors from rat striatum and rat pheochromocytoma PC12 cells: Characterization with radioligand binding and by activation of adenylate cyclase. Mol Pharmacol. 1992;41:352–359. [PMC free article] [PubMed] [Google Scholar]
- Jacobson KA, Barone S, Kammula U, Stiles GL. Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. J Med Chem. 1989;32:1043–1051. doi: 10.1021/jm00125a019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jacobson KA, Stiles GL, Ji X-D. Chemical modification and irreversible inhibition of striatal A2a-adenosine receptors. Mol Pharmacol. 1992;42:123–133. [PMC free article] [PubMed] [Google Scholar]
- Jacobson KA, Gallo-Rodriguez C, Melman N, Fischer B, Maillard M, van Bergen A, van Galen PJM, Karton Y. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem. 1993;36:1333–1342. doi: 10.1021/jm00062a005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jarvis MF, Schutz R, Hutchison AJ, Do E, Sills MA, Williams M. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther. 1989;251:888–893. [PubMed] [Google Scholar]
- Linden J, Jacobson MA, Hutchins C, Williams M. Adenosine receptors. In: Peroutka SJ, editor. Handbook of Receptors and Channels. Vol. 1. Boca Raton, FL: CRC Press; 1993. G-Protein-Linked Receptors. in press. [Google Scholar]
- Lohse MJ, Elger B, Lindenborn-Fotinos J, Klotz KN, Schwabe U. Separation of solubilized A2 adenosine receptors of human platelets from non-receptor [3H]NECA binding sites by gel filtration. Naunyn Schmiedebergs Arch Pharmacol. 1988;337:64–68. doi: 10.1007/BF00169478. [DOI] [PubMed] [Google Scholar]
- Maenhaut C, Van Sande J, Libert F, Abramowicz M, Parmentier M, Dumont JE, Vassart G, Schiffmann S. RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem Biophys Res Comm. 1990;173:1169–1178. doi: 10.1016/s0006-291x(05)80909-x. [DOI] [PubMed] [Google Scholar]
- McCabe RT, Skolnick P, Jacobson KA. FITC-APEC: A fluorescent ligand for A2-adenosine receptors. J Fluoresc. 1993;2:217–223. doi: 10.1007/BF00865279. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Munson PJ, Rodbard D. Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980;107:220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
- Niiya K, Jacobson KA, Silvia SK, Olsson RA. Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors. Naunyn-Schmiedeberg’s Arch Pharamacol. 1993;347:521–526. doi: 10.1007/BF00166745. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Olsson RA, Pearson JD. Cardiovascular purinoceptors. Physiol Rev. 1990;70:761–845. doi: 10.1152/physrev.1990.70.3.761. [DOI] [PubMed] [Google Scholar]
- Ramkumar V, Olah ME, Jacobson KA, Stiles GL. De-sensitization of both A1 and A2 adenosine receptors in DDT1, MF-2 smooth muscle cells. Mol Pharmacol. 1991;40:639–647. [PMC free article] [PubMed] [Google Scholar]
- Shimada J, Suzuki F, Nonaka H, Ishii A, Ichikawa S. (E)-1,3-Dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines—potent and selective adenosine-A2 antagonists. J Med Chem. 1992;35:2342–2345. doi: 10.1021/jm00090a027. [DOI] [PubMed] [Google Scholar]
- Stehle JH, Rivkees SA, Lee JJ, Weaver DR, Deeds JD, Reppert SM. Molecular cloning and expression of the cDNA for a novel A2-adenosine receptor subtype. Mol Endocrinol. 1992;6:384–393. doi: 10.1210/mend.6.3.1584214. [DOI] [PubMed] [Google Scholar]
- Stone GA, Jarvis MF, Sills MA, Weeks B, Snowhill EW, Williams M. Species differences in high-affinity adenosine A2 binding sites in striatal membranes from mammalian brain. Drug Dev Res. 1988;15:31–46. [Google Scholar]
- Van Galen PJM, Stiles GL, Michaels G, Jacobson KA. Adenosine A1 and A2 receptors: Structure-function relationships. Med Res Rev. 1992;12:423–471. doi: 10.1002/med.2610120502. [DOI] [PMC free article] [PubMed] [Google Scholar]





